Paliperidone in the treatment of delirium: Results of a prospective open-label pilot trial

Ho Kyoung Yoon, Yong Ku Kim, Changsu Han, Young Hoon Ko, Heon Jeong Lee, Do Young Kwon, Leen Kim

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)


Paliperidone in the treatment of delirium: results of a prospective open-label pilot trial. Objective: Delirium is a life-threatening neuropsychiatric syndrome characterised by disturbances in consciousness, attention, cognition and perception. Antipsychotics are considered the drugs of choice in managing the symptoms of delirium. Paliperidone is a benzisoxazole derivative and the principal active metabolite of risperidone. In this study, we aimed to evaluate the efficacy of paliperidone for the treatment of delirium. Methods: A prospective open-label study of paliperidone for delirium treatment was performed with 6-day follow-up. Fifteen patients who met Diagnostic and Statistical Manual of Mental disorders, Fourth Edition criteria for delirium and had a score of 13 on the Delirium Rating Scale were recruited. The starting dose was 3 mg once a day and the dose was adjusted depending on the status of delirium. Daily assessments of the severity of delirium were evaluated using Memorial Delirium Assessment Scale (MDAS). Results: The mean daily maintenance dose of paliperidone was 3.75 ± 1.06. The MDAS scores before and after treatment (day 7) were 23.60 ± 6.31 and 11.33 ± 5.45 (t = 6.78, p < 0.001), respectively. The intensity of delirium showed a statistically significant reduction in MDAS scores from the first day of treatment. No serious adverse effects were observed, and none of the patients discontinued paliperidone because of adverse effects. Conclusions: This study shows that low-dose paliperidone is effective in reducing behavioural disturbances and symptoms in delirium and is well tolerated in delirious patients. This trial is an open-label study with a small sample size, and further controlled studies will be necessary.

Original languageEnglish
Pages (from-to)179-183
Number of pages5
JournalActa Neuropsychiatrica
Issue number4
Publication statusPublished - 2011 Aug


  • DRS
  • MDAS
  • delirium
  • paliperidone

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry


Dive into the research topics of 'Paliperidone in the treatment of delirium: Results of a prospective open-label pilot trial'. Together they form a unique fingerprint.

Cite this